Search Results - Therapeutics

40 Results

Sort By:

Discovery of Well Defined Sulfated Glycopolymers as Specific Heparanase Inhibitors for Cancer Therapeutics

The remodeling of the extracellular matrix has been shown to be highly upregulated in cancer and inflammation and is critically linked to the processes of invasion and metastasis. The finding that heparanase is elevated in a wide variety of tumor types and is subsequently linked to the development of pathological processes has led to an explosion of...

Published: 12/2/2020 | Inventor(s): Hein Nguyen, Ravi Loka, Eric Sletten, Israel Vlodavsky

Keywords(s): Cancer, Cancer Therapies, Pharmaceuticals, Therapeutics

Category(s): Life Science, Oncology, Pharmaceuticals, Therapeutics

Identification of Galeterone's mechanism of action leading to novel treatment therapies for castrate resistant prostate cancer (CRPC)

Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (HRPC), is a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT). The need for effective therapies for these difficult to treat cancers is gaining prominence in the prostate cancer market. The global CRPC market is poised...

Published: 11/19/2020 | Inventor(s): Qingping Dou, Huanjie Yang, Elisabeth Heath

Keywords(s):

Category(s): Life Science, Oncology, Pharmaceuticals, Receptors/targets, Process/Procedure, Small molecule, Therapeutics

Fc-folate conjugate for the treatment of triple negative breast cancer

Approximately 13% of women in the United States will develop breast cancer according to the American Cancer Society. That makes breast cancer the second leading cause of cancer death in women right behind lung cancer. Triple negative breast cancer (TNBC) represents about 10 – 20% of all breast cancers. Triple negative refers to cancer cells...

Published: 10/31/2024 | Inventor(s): Cecilia Speyer

Keywords(s): Anti-cancer, Breast Cancer, Cancer, Cancer Therapies

Category(s): Antibodies, Assays, Biology, Biomedical, Chemical Processing/Synthesis, Diseases, Drug Delivery, Life Science, Oncology, Protein/peptides, Receptors/targets, Small molecule, Therapeutics

Drugs that disrupt interactions between ELK1 and the androgen receptor to suppress growth of both early stage and castration resistant prostate cancer

Background:Prostate cancer is the second-most commonly diagnosed cancer among men and the fifth most common cause of male cancer death worldwide. Although tumors are often initially sensitive to medical or surgical therapies that decrease levels of testosterone, continued disease progression generally represents a transition to the lethal variant. In...

Published: 10/22/2019 | Inventor(s): Manohar Ratnam, Rayna Rosati, Mugdha Patki

Keywords(s):

Category(s): Life Science, Therapeutics, Oncology, Drug Discovery, Pharmaceuticals

Topical treatment with TGFbeta3 to facilitate skin and corneal wound healing in diabetic patients

Background: Diabetes affects approximately 170 million people worldwide, including 20.8 million in the USA, and by 2030 these numbers are projected to double. Diabetics often experience slow or limited wound healing. Slow wound healing allows longer time for the development of infections and can contribute to the formation of bed sores and ulcers....

Published: 9/16/2019 | Inventor(s): Fu-Shin Yu

Keywords(s): Diabetes

Category(s): Medical, Biologicals, Biomedical, Drug Discovery, Metabolic disorders, Protein/peptides, Therapeutics, Life Science

Using nanotechnology to target aggressive cancers with a novel small molecule inhibitor of the DNA damage tolerance pathway

Background: Nanotechnology is emerging as a promising tool to target cancer cells. Gold nanoparticles (GNPs) are preferentially taken up by cancer cells when injected into the blood stream and their safety has been demonstrated in human clinical trials. WSU researchers have designed a unique nanoparticle conjugate that combines a GNP with a small molecule...

Published: 8/29/2018 | Inventor(s): Malathy Shekhar, Guangzhao Mao, Yanhua Zhang

Keywords(s):

Category(s): Life Science, Oncology, Small molecule, Receptors/targets, Nano-based, Drug Delivery, Therapeutics, Diseases

An in vivo QQ-systemic protein delivery technology and applications

BackgroundThis invention contains a new composition of our researchers’ previously patented QQ-protein delivery technology and the in vivo applications of this protein delivery technology via systemic administered proteins for cancer diagnosis and therapy. Many proteins and peptides are used as highly specific and effective therapeutic agents....

Published: 11/9/2021 | Inventor(s): Jianjun Wang, Qianqian Li, Quan Jiang, Feng Jiang, Michael Chopp

Keywords(s): Cancer Therapies, Drug Delivery

Category(s): Diagnostics, Drug Delivery, Life Science, Oncology, Research tools, Therapeutics

Inhibitors of the ubiquitin E3 ligase BCA2 as anti-cancer therapeutic agents

Background:Breast cancer associated protein 2 (BCA2) is a ubiquitin E3 ligase found in invasive breast cancer. Studies have shown that by decreasing its activity, breast cancer cell growth and invasiveness are diminished. Targeting this ligase and inhibiting its activity could play a role in treatment of breast cancer. A molecular approach to inhibiting...

Published: 3/12/2018 | Inventor(s): Angelika Burger, Andrew Westwell

Keywords(s): Analog or Analogue, Breast Cancer, Cancer, Disease, Drug Target, Enzyme

Category(s): Diseases, Oncology, Therapeutics, Life Science, Research tools

Anti-Cancer Activity of a 2,5-Substituted Pyrimidine

This technology is a novel class of compounds that induce apoptosis in cancerous cells. BackgroundARR molecules (adamantyl-substituted retinoid-related) are a unique class of compounds which have been found to induce apoptosis, or cell death, in a large number of tumor types. SHP plays a role in cellular proliferation. Molecules that Interfere with...

Published: 12/7/2022 | Inventor(s): Joseph Fontana, Ramzi Mohammad, Lulu Farhana, Amro Aboukameel, Marcia Dawson, Zebin Xia

Keywords(s): Analog or Analogue, Anti-cancer

Category(s): Life Science, Oncology, Therapeutics, Diseases

SH80 Combinations

BackgroundSH35/SH80 evolved from an effort to improve upon the anti-tumor activity of XK469. XK469 is a compound, currently in Phase 1 clinical trials. The clinical trials include patients with bladder, breast, colorectal, esophageal, head and neck, kidney, liver, lung, mesothelioma, pancreas and sarcoma cancers. Moving a chlorine atom from one position...

Published: 3/2/2022 | Inventor(s): Lisa Polin

Keywords(s): Anti-cancer, Compound

Category(s): Life Science, Oncology, Therapeutics

1 2 3 4